Kausik K. Ray

Nov 18, 2024 | radcliffecardiology.com | Harriette Van Spall |Kausik K. Ray |Mohammed Sallam |Derek L Connolly

AHA Conference 2024 — Key findings from the ZODIAC trial investigating the role of a decision support system in optimising lipid-lowering therapy for ACS patients. Dr Harriette Van Spall (McMaster University, CA) sits down with Prof Kausik Ray (Imperial College London, UK) to discuss the findings from the randomized controlled ZODIAC trial assessing decision support systems (DSS) in optimising lipid-lowering therapies in patients with acute coronary syndrome (ACS).

Oct 14, 2024 | consultantlive.com | Kausik K. Ray |Gerald Watts

Emerging RNAi-Based Therapies for FCS, Dyslipidemia - Episode 7Published on: , Panelists discuss how various new and developing approaches for treating familial chylomicronemia syndrome are emerging, and emphasize the importance for clinicians to integrate these advancements into practice while staying current with ongoing research and evolving treatment strategies.

Oct 7, 2024 | consultantlive.com | Kausik K. Ray |Gerald Watts

Emerging RNAi-Based Therapies for FCS, Dyslipidemia - Episode 6Published on: , Panelists discuss how the SHASTA-2 study evaluated the efficacy and safety of plozasiran in reducing triglyceride levels and APOC3 in familial chylomicronemia syndrome, comparing outcomes with the placebo group and assessing implications for treating severe hypertriglyceridemia and preventing pancreatitis. Video content above is prompted by the following:Please provide a brief overview of the SHASTA-2 study.

Oct 7, 2024 | consultantlive.com | Kausik K. Ray |Gerald Watts

Emerging RNAi-Based Therapies for FCS, Dyslipidemia - Episode 5Published on: , Panelists discuss how various new and developing approaches for treating familial chylomicronemia syndrome are emerging, and emphasize the importance for clinicians to integrate these advancements into practice while staying current with ongoing research and evolving treatment strategies.

Oct 7, 2024 | hcplive.com | Kausik K. Ray |Gerald Watts

OpinionVideoOctober 7, 2024Author(s): Gene therapies, antisense oligonucleotides, and RNA interference technologies are promising approaches for FCS treatment, focusing on triglyceride reduction and symptom management. Clinicians should engage in continuous education, attend conferences, and collaborate with specialists to integrate emerging therapies into practice. A multidisciplinary approach and decision-support tools can enhance the management of FCS patients, improving outcomes.